Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin cardiovascular and renal outcomes study in type 2 diabetes with moderate renal impairment
NL-OMON50440Phase 3Active, not recruiting
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: 3-point major adverse cardiovascular events non-inferiority and Cardiovascular death or hospitalization for heart failure. Started Jun 2018; status: active, not recruiting.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON50440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50440.